Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07168993 · View on ClinicalTrials.gov ↗

Study Summary

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

Conditions Studied

Interventions

  • OTHER Standard medical treatment

Study Locations (3)

Texas

  • Audie Murphy VA Medical Center — San Antonio
  • Brooke Army Medical Center — San Antonio

Pennsylvania

  • Clinical Research Associates of Central Pennsylvania — DuBois

Trial Details

FieldValue
Enrollment Target 2,063 participants
Start Date 2026-02-25
Est. Completion 2029-07-01
Phase NA

Sponsor

bioAffinity Technologies

30 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07168993

The ClinicalTrials.gov registry entry for NCT07168993 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,063 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is bioAffinity Technologies, which has 30 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Lung Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention — of which Standard medical treatment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07168993 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Texas, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07168993 about?

NCT07168993 is a clinical study titled "Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.". Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

What is the current status of trial NCT07168993?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,063 participants. The study started on 2026-02-25. Estimated completion is 2029-07-01.

What conditions does trial NCT07168993 study?

This clinical trial studies the following conditions: Lung Cancer (Diagnosis). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07168993?

The interventions under investigation include: Standard medical treatment (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07168993?

This trial is sponsored by bioAffinity Technologies, which has 30 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07168993 being conducted?

This trial has 3 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial